Table 2.
Clinical Characteristics of Pulmonary Arterial Hypertension Cohort
| Females | N | Males | N | |
|---|---|---|---|---|
| mPAP (mmHg)a | 40 (20–48) | 51 | 36 (32–43) | 14 |
| PVR (WU)a | 4.6 (3.0–6.7) | 50 | 4.7 (3.7–6.2) | 14 |
| RVCI (L/min · m2)a | 3.3 (2.8–3.8) | 51 | 3.1 (2.5–3.4) | 14 |
| RVSVi (mL/m2)b | 30 (27–41) | 29 | 31 (17–48) | 7 |
| RVEF (%)b | 40 (28–49) | 29 | 39 (24–41) | 7 |
| 6MWD (m) | 352 (270–399) | 35 | 274 (194–398) | 7 |
| BNP (pg/mL) | 84 (38–214) | 48 | 73 (35–174) | 14 |
| WBC ( × 109/L) | 6.4 (5.2–7.7) | 50 | 6.9 (5.4–9.8) | 14 |
The data presented as median (IQR).
a
Derived from right heart catheterization.
b
Derived from cardiac magnetic resonance imaging.
6MWD, six-minute walk distance; BNP, B-type natriuretic peptide; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; RVCI, right ventricle cardiac index; RVEF, right ventricular ejection fraction; RVSVi, indexed right ventricular stroke volume; WBC, white blood cell.